Ajay Gopal, Marek Trneny, Laurie Sehn, Julie Wu, Michael Arbushites, Oscar Bortolami, Stefano Luminari. "Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment." Blood (2025). https://doi.org/10.1182/blood-2025-1819